Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Current Signal: BUY (auto-tracking)
4.81% $25.27
America/New_York / 23 apr 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 3 752.39 mill |
EPS: | -5.34 |
P/E: | -4.73 |
Earnings Date: | May 02, 2024 |
SharesOutstanding: | 148.49 mill |
Avg Daily Volume: | 1.707 mill |
RATING 2024-04-23 |
---|
B- |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Buy | |
Return On Equity: | Strong Buy | |
Return On Asset: | Sell | |
DE: | Strong Sell | |
P/E: | Sell | |
Price To Book: | Strong Sell |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | ||||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -4.73 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.80x |
Company: PE -4.73 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
N/A |
N/A |
Expected Trading Range (DAY) |
---|
$ 24.33 - 26.21 ( +/- 3.72%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-02-28 | Lewis William | Buy | 50 000 | Common Stock |
2024-02-28 | Lewis William | Buy | 50 000 | Stock Option (right to buy) |
2024-02-28 | Sharoky Melvin Md | Sell | 3 600 | Common Stock |
2024-02-28 | Sharoky Melvin Md | Buy | 1 200 | Common Stock |
2024-02-28 | Sharoky Melvin Md | Buy | 1 200 | Common Stock |
INSIDER POWER |
---|
36.58 |
Last 100 transactions |
Buy: 1 120 971 | Sell: 555 042 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $25.27 (4.81% ) |
Volume | 2.02 mill |
Avg. Vol. | 1.707 mill |
% of Avg. Vol | 118.51 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $28.45 | N/A | Active |
---|
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary arterial hypertension and other rare pulmonary disorders. Insmed Incorporated was founded in 1988 and is headquartered in Bridgewater, New Jersey.